Considering the quality of the drug, 6 month dosing after initial two injections and the pricing is relatively low, every patient would have to eventually give it deep consideration.
In the end I see it as a large threat to Biogen but less to copaxone once their pricing falls.
The reasons? Ocrevus' high efficacy in both forms of the disease, its “reasonable” safety profile and its 6-month dosing schedule, which tops many of its peers in the convenience department. Its price—$65,000 per year, a 20% discount, on average, to its rivals—doesn’t hurt
